Please login to the form below

Not currently logged in
Email:
Password:

larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for

Latest news

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    Loxo gained its first ever drug approval in late November with Vikrakvi (larotrectinib), now FDA approved to treat any solid tumour that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    Also worth a mention is Lox/Bayer’s Vitrakvi (larotrectinib), which became the second drug to be approved based on a biomarker across different types of tumours rather than the location

  • Loxo, Bayer get FDA okay for biomarker-driven cancer drug Loxo, Bayer get FDA okay for biomarker-driven cancer drug

    Vikrakvi (larotrectinib) – partnered with Bayer – has been cleared to treat any solid tumour that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, which causes the production of TRK, a family ... Studies have revealed that

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    Its pipeline is headed by larotrectinib which has a BTD for patients with locally advanced or metastatic solid tumours harbouring an NTRK gene fusion mutation and has already been submitted for ... Last year, Bayer paid an impressive $400m upfront with

  • Loxo, Bayer get quick FDA review for ‘precision’ cancer drug Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

    Bayer and Loxo hopeful about novel biomarker-led cancer treatment. Loxo Oncology and Bayer should hear from the FDA about their tumour biomarker-targeted cancer drug larotrectinib by 26 November, after ... TRK inhibitor Larotrectinib is being reviewed by

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics